Skip to main content
DURECT Corporation (DRRX)
NASDAQ: DRRX · Real-Time Price · USD
0.865
-0.038 (-4.21%)
Nov 21, 2024, 1:15 PM EST - Market open

DURECT Revenue

DURECT had revenue of $1.93M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $8.59M, down -6.53% year-over-year. In the year 2023, DURECT had annual revenue of $8.55M, down -55.67%.

Revenue (ttm)
$8.59M
Revenue Growth
-6.53%
P/S Ratio
3.21
Revenue / Employee
$148,172
Employees
58
Market Cap
26.86M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20238.55M-10.74M-55.67%
Dec 31, 202219.28M5.31M37.96%
Dec 31, 202113.98M-16.13M-53.58%
Dec 31, 202030.11M5.04M20.09%
Dec 31, 201925.07M9.80M64.15%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Nortech Systems 135.57M
ImmuCell 23.84M
Surrozen 10.00M
Marker Therapeutics 5.40M
Daré Bioscience 1.88M
Longeveron 1.85M
SAB Biotherapeutics 1.51M
OneMedNet 1.02M
Revenue Rankings

DRRX News

More News